Navigation Links
FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters
Date:9/14/2010

HAMILTON, N.J., Sept. 14 /PRNewswire/ -- MedAvante, Inc., the leader in centralized expert evaluation of CNS disorders, announced today that the U.S. Food and Drug Administration (FDA) has approved the first New Drug Application (NDA) for a psychiatric medication including primary outcome data collected by MedAvante centralized raters.

Johnson and Johnson Pharmaceutical R&D, a Johnson & Johnson company, submitted the NDA for the drug paliperidone palmitate, now known as Invega Sustenna®, for the acute and maintenance treatment of schizophrenia.

In one of the NDA multicenter studies, primary outcome measures were pooled from two groups, one within and one outside the United States.  MedAvante centralized raters administered the assessments for the U.S. portion of the study. Outside the US, local site-based raters administered the assessments. The study, including the use of MedAvante Centralized Ratings, was recently described in the Journal of Clinical Psychopharmacology(1) and referenced in the FDA's Summary Basis of Approval (SBA).*

"The approval of this drug, based on a data package that included the use of centralized psychiatric raters, demonstrates the increasing regulatory acceptance of this tool," said Scott Gottlieb, MD, former Deputy Commissioner of the FDA and member of the MedAvante Board of Directors.

"Other areas of drug regulation have shown a preference for centralizing the assessment of subjective endpoints to achieve greater standardization, consistency, and quality in the data," said Dr. Gottlieb. "Now there is every reason to believe that the subjective and variable manner in which patients in CNS clinical trials have historically been evaluated by site-based raters will become subject to similar improvements."

MedAvante's proprietary methodology, Remote Centralized Ratings™, systematically addresses the sources of bias that can make it difficult to separate placebo response from true drug response during many types of CNS clinical trials.

According to Scott A. Reines MD, PhD, a senior scientific advisor to MedAvante and former Senior Vice President for Clinical Neuroscience at J&J Pharmaceutical R&D during the conduct of the paliperidone palmitate program, "One of the major obstacles in schizophrenia studies has been the high placebo response frequently observed in US clinical trials.  Centralized ratings were utilized in the paliperidone palmitate study in order to help address this issue."  

"Working with MedAvante in this study was well worth the effort. It helped to provide external validation in the measurements of efficacy for paliperidone," said Ronald Brenner, MD, and Principal Investigator at Neurobehavioral Research, Inc. in Cedarhurst, New York.

"Because MedAvante centralized raters are continuously trained, monitored, and calibrated as a single, standardized cohort, they are more effective in determining patient diagnosis and eligibility according to protocol, more accurate in setting accurate baseline scores, and better able to raise the level of inter-rater reliability," said Paul Gilbert, Chief Executive Officer of MedAvante. "Achieving this NDA is an important milestone in the more than 8 years of work to fine-tune our methodology and working with nearly 300 investigative sites in 25 countries around the world."

*http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022264s000medr.pdf

About MedAvante

MedAvante is the premier global provider of centralized expert psychiatric rating and monitoring services to the pharmaceutical, biotechnology and medical device industries. Our flagship service, MedAvante's Remote Centralized Ratings™ are real-time assessments, either by telephone or videoconference, of subjects in global drug trials. Centralizing the assessors and blinding them to study protocols, results in a level of standardization, calibration and objectivity that is not achievable with a decentralized group of study raters participating from unconnected investigative sites. In addition to Centralized Ratings, the company provides Continuous Quality Control CQC, a monitoring service in which expert calibrated trainers review site-based study interviews via audio and video.  MedAvante's solutions help sponsors achieve increased drug effect and reduced trial failure rates, enabling them to bring better drugs to market faster. MedAvante operates facilities in Hamilton, NJ; Madison, WI; and Moscow, Russia.

(1)  Pandina, G. J., Lindenmayer, J. P. , Lull, J., Lim, P., Gopal, S.,  Herben, V., Kusumakar, V., Yuen, E., & Palumbo, J.  (2010). A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.  Journal of Clinical Psychopharmacology, 30, 235 – 244.  doi: 10.1097/JCP.ob013e3181dd3103


'/>"/>
SOURCE MedAvante, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
2. FDA Approves Pediatric Use of Chemical Poisoning Treatment
3. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
4. FDA Approves Vaccines for the 2010-2011 Influenza Season
5. FDA Approves Strativa Pharmaceuticals Zuplenz® (ondansetron) Oral Soluble Film
6. FDA Approves Sagent Pharmaceuticals Heparin Sodium Injection, USP
7. U.S. FDA Approves Improved Performance of Riverain Medicals OnGuard Chest X-ray Computer-Aided Detection Technology
8. FDA Approves New Injectable Osteoporosis Treatment for Postmenopausal Women
9. FDA Approves New Treatment for Late-Onset Pompe Disease
10. FDA Approves Cefepime for Use In B. Brauns DUPLEX(R) System
11. U.S. FDA Approves Natazia(TM), a New Oral Contraceptive for the Prevention of Pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016 The global  gamma ... billion by 2022, according to a new report ... towards a healthy lifestyle is expected to drive ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... health treatment expenditure has urged consumers to switch ...
(Date:4/26/2016)... FLINT, Mich. , April 26, 2016 ... the promotion of Jennifer Hagerman , Pharm D., ... In her growing role at Diplomat, Hagerman will continue ... of the company that delivers custom education and training ... to the specialty pharmacy industry. Diplomat University also houses ...
(Date:4/26/2016)... 26, 2016 US demand for infection ... 4.9 percent annually to $27.6 billion in 2020.  ... to decrease rates of healthcare-associated infections (HAIs) will ... and services.  Although declining, the overall rate of ... levels set by the CDC.  Recent statistics indicate ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to ... and podcasted thereafter . Dr. Bernie Siegel, author of a plethora of ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... reveals that infants born with severe congenital diaphragmatic hernia have better survival rates ... with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, ...
(Date:4/29/2016)... ... April 29, 2016 , ... World Patent Marketing , ... exercise invention which aids in proper muscle development. , "The Gym & Exercise ... Director of World Patent Marketing. "Globalization has threatened the future growth of the ...
(Date:4/29/2016)... ... ... New York City based oral and maxillofacial surgeon Dr. Majid Jamali is an ... obstructive sleep apnea. Dr. Jamali is proud to offer this permanent solution to patients who ... both jaw bones. This surgery is performed to correct the alignment of the jaw. It ...
(Date:4/29/2016)... ... 29, 2016 , ... Innovations with Ed Begley Jr., announced ... airing third quarter 2016 via Discovery Channel. Dates and show times TBA. , ... located in Greenwood, Wisconsin applies product research and development and continuous technological improvements ...
Breaking Medicine News(10 mins):